Product Detailed Description

liposomal Ubiquinol 70% — High Bioavailability Active CoQ10 Supplement

Product Overview

Liposomal Ubiquinol 70% is a premium-grade dietary supplement ingredient delivering ubiquinol in an advanced liposomal delivery system. Ubiquinol (CAS 992-78-9), also known as reduced Coenzyme Q10 or dihydrocoenzyme Q10, is the fully reduced, electron-rich form of CoQ10, with the molecular formula C₅₉H₉₂O₄ and a molecular weight of 865.4 g/mol. It is the biologically active form of CoQ10 that directly neutralizes lipid peroxyl radicals with efficacy exceeding vitamin E in TEAC/FRAP/DPPH assays.

CoQ10 exists in two interconvertible forms: ubiquinone (the oxidized form) and ubiquinol (the reduced form). Ubiquinol is the dominant circulating form in healthy human plasma, and its ratio to ubiquinone is considered a biomarker for oxidative stress. While ubiquinone is the form used in most clinical trials due to its greater stability, ubiquinol offers the advantage of being directly functional without requiring enzymatic conversion. Ubiquinol achieves 72% higher steady-state plasma CoQ10 levels compared to ubiquinone at equivalent oral doses.

Why Liposomal Technology?

Ubiquinol presents exceptional formulation challenges. The molecule is highly sensitive to oxidation, light, and heat, and readily converts back to ubiquinone under ambient conditions. It has extremely low aqueous solubility, high crystallinity, and poor oral bioavailability. These factors severely limit the stability, shelf-life, and clinical utility of conventional ubiquinol supplements.

Liposomal encapsulation provides four critical advantages:

1. Enhanced Stability and Protection — Metazomal CoQ10 (MCQ) was developed using Metazome technology, in which CoQ10 was incorporated into phospholipid bilayers reinforced with gum arabic nanospheres and converted into a dry, reconstitutable liposomal powder by spray drying. The formulation retained >90% of CoQ10 after 180 days at room temperature, demonstrating superior stability compared to conventional ubiquinol forms.

2. Enhanced Bioavailability — In a randomized, open-label, crossover study in healthy volunteers, liposomal CoQ10 demonstrated significantly improved pharmacokinetics compared with conventional CoQ10, including a 4.3-fold increase in AUC₀–ₜ, a 3.6-fold increase in Cmax, prolonged Tmax, extended half-life, and a lower elimination rate constant (p < 0.01).

3. Nanoscale Delivery System — MCQ formed nanosized (~185 nm), spherical vesicles with high encapsulation efficiency (88.6 ± 2.3%), favorable loading capacity (14.2 ± 0.8%), and strong electrostatic stability (zeta potential −41.16 mV). The amorphous molecular dispersion of CoQ10 within the liposomal matrix overcomes the crystallinity that limits dissolution and absorption.

4. Direct Antioxidant Activity — Unlike ubiquinone, which shows virtually no direct antioxidant activity, ubiquinol directly neutralizes lipid peroxyl radicals, providing immediate antioxidant protection without requiring prior enzymatic conversion.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% ubiquinol by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Phospholipid bilayer encapsulation achieves 88.6% encapsulation efficiency and nanoscale particle size (~185 nm), dramatically improving ubiquinol stability and oral bioavailability.

• Superior Pharmacokinetics — Liposomal CoQ10 demonstrated a 4.3-fold increase in AUC₀–ₜ and a 3.6-fold increase in Cmax versus conventional CoQ10 in human pharmacokinetic studies.

• Direct Antioxidant Activity — Ubiquinol directly neutralizes lipid peroxyl radicals with efficacy exceeding vitamin E, without requiring enzymatic conversion from ubiquinone.

• Higher Steady-State Levels — Ubiquinol achieves 72% higher steady-state plasma CoQ10 levels compared to ubiquinone at equivalent oral doses.

• Clinically Validated for Heart Failure — The Q-SYMBIO trial demonstrated that CoQ10 at 300 mg/day (100 mg three times daily) added to standard therapy is safe, relieves symptoms, and reduces major cardiovascular events.

• Superior Stability — Liposomal ubiquinol retained >90% of CoQ10 after 180 days at room temperature.

• Water-Dispersible — Suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies and commercial products commonly recommend 100–300 mg of ubiquinol per day. Most trials recommend a supplement dosage range between 100 and 300 mg/day (e.g., 100 mg three times per day). The Q-SYMBIO trial, a multicenter randomized controlled study of 420 heart failure patients, demonstrated that adding CoQ10 at 100 mg orally three times daily to standard therapy is safe, relieves symptoms, and reduces major cardiovascular events. An adequate dose (on average 200–300 mg per day with a plasma concentration of at least 3 µg/mL) and duration of treatment (at least several months) are crucial for therapeutic efficacy. The observed safety level is 1,200 mg/day based on clinical data. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.